Tesamorelin vs CJC-1295: Two Approaches to GHRH Stability

Both tesamorelin and CJC-1295 are synthetic analogs of growth hormone-releasing hormone (GHRH 1-29) engineered for extended half-life. They achieve this through fundamentally different strategies.

Tesamorelin adds a trans-3-hexenoyl group at the N-terminus, which resists DPP-IV cleavage at the Ala²-Asp³ bond. The molecule retains the native 44-residue length and binds the GHRH receptor with comparable affinity to native GHRH.

CJC-1295 (often with or without DAC — Drug Affinity Complex) uses a different strategy: a maleimido-propionic acid linker that covalently binds endogenous albumin in serum. The albumin-bound form is protected from enzymatic degradation, dramatically extending circulating half-life.

For in vitro pharmacology, both peptides activate the GHRH receptor in pituitary somatotrope cell lines (e.g. GH3) with similar cAMP-accumulation EC50 values. The half-life advantage only manifests in serum-stability or whole-animal models — not in short-duration cell-culture assays.

For research use only.